Esperion Therapeutics
A US pharma company developing medicines to improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
Esperion was founded in 2008, and has since developed its primary product—bempedoic acid—which is an orally available small molecule designed to lower elevated levels of LDL-C.
Latest Esperion Therapeutics News & Features
24 May 2024
4 January 2024
17 March 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze